SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
Portfolio Pulse from
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has received FDA approval for its new product, ArbliTM, a losartan potassium oral suspension. This is the first FDA-approved ready-to-use oral liquid losartan in the U.S., targeting hypertension, stroke risk reduction, and diabetic nephropathy.
March 18, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has received FDA approval for ArbliTM, a novel losartan potassium oral suspension. This approval positions SCNX to capture a share of the $1.5 billion losartan market.
The FDA approval of ArbliTM, a unique product in the U.S. market, is likely to positively impact SCNX's stock price. The product's novelty and the size of the losartan market suggest significant revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100